Business Context and Reporting Period
Company: Utah Medical Products, Inc. (UTMD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2009
Business Overview: UTMD manufactures and markets single-use specialty medical devices, including obstetric, neonatal, and electrosurgery products. The company operates manufacturing facilities in the U.S. and Ireland.
Key Financial Metrics
All figures in thousands, except per share data.
| Metric | Three Months Ended June 30, 2009 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Net Sales | $6,305 | $12,750 |
| Gross Profit | $3,335 | $6,835 |
| Operating Income | $2,213 | $4,672 |
| Net Income | $1,504 | $3,096 |
| Diluted EPS | $0.42 | $0.86 |
| Cash and Investments | $17,041 (Total Current Assets: $24,961) | |
| Total Debt | $1,770 (Current: $257; Long-term: $1,513) | |
| Working Capital | $22,596 |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 11% in Q2 2009 and 9% in the first half (1H) of 2009 compared to the same periods in 2008.
- International Sales: Dropped 27% in Q2 and 22% in 1H, primarily due to the cessation of purchases of custom blood pressure monitoring kits by the largest international customer.
- Domestic Sales: Declined 4% in Q2 and 3% in 1H, attributed to increased competition and restrictive Group Purchasing Organization (GPO) agreements affecting obstetric devices.
- Profitability: Net income fell 22% in Q2 and 19% in 1H. Gross profit margins compressed slightly (52.9% in Q2 2009 vs. 55.1% in Q2 2008) due to lower fixed overhead absorption, higher material costs, and competitive pricing.
- Non-Operating Income: Decreased significantly due to patent expirations eliminating royalty income and lower interest rates reducing investment income.
- Balance Sheet: Cash increased to $802 from $97 at year-end 2008. Inventory rose to $4,158 (from $3,275) due to bulk raw material purchases and excess labor capacity utilization.
Guidance, Outlook, and Risks
- Management Outlook: Management has lowered full-year 2009 projections, expecting sales, gross profits, and EPS to decline 7-8% compared to 2008.
- Capital Allocation: The company plans to utilize excess cash for dividends, share repurchases, and potential strategic acquisitions. In 1H 2009, the company repurchased 5,367 shares and paid $830 in dividends.
- Key Risks:
- Market Dynamics: Reliance on "physician-preference" products is threatened by hospital administrators making purchasing decisions via GPOs.
- Competition: Risk of product displacement by competitors offering lower-priced alternatives.
- Customer Concentration: Significant exposure to the largest international customer, whose purchasing patterns heavily impact revenue.
- Currency: Exposure to Euro/USD exchange rate fluctuations affecting the Irish subsidiary's debt and revenue.
Investor Verification Checklist
- Customer Concentration: Verify the status of the largest international customer and the likelihood of regaining the custom blood pressure monitoring kit business.
- Inventory Levels: Monitor inventory turns to ensure the $883 increase in inventory (driven by bulk buying and soft demand) does not lead to future write-downs.
- GPO Impact: Assess the long-term effect of Group Purchasing Organization agreements on domestic obstetric device sales.
- Debt Repayment: Track the repayment schedule of the Irish subsidiary's Euro-denominated note payable ($1,253k remaining).
- Share Repurchases: Confirm if the company will continue its open market share repurchase program given the lowered earnings outlook.